Arrowhead Pharmaceuticals. has been granted a patent for novel linking agents that enhance the attachment of targeting groups and delivery agents to oligonucleotides. These agents demonstrate improved reaction yields, stability, and biological activity, particularly for RNA interference (RNAi) applications. GlobalData’s report on Arrowhead Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arrowhead Pharmaceuticals, Targeted cancer therapy was a key innovation area identified from patents. Arrowhead Pharmaceuticals's grant share as of July 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12065458B2 encompasses a series of claims related to a compound designated as Formula III, along with its pharmaceutically acceptable salts. The claims specify variations of the compound based on the substituent X, which can be either oxygen (O) or sulfur (S). Additionally, the claims detail the structural components L1, L2, L3, and L4, indicating that these components can take on specific forms or structures, although the exact nature of these components is not fully disclosed in the provided text. The patent also outlines methods for reacting the compound of Formula III, with similar variations for the substituent Y, which can also be O or S, and reiterates the structural specifications for L1, L2, L3, and L4.
Furthermore, the patent includes claims for a method of reacting a compound of Formula II, again allowing for variations in the substituent X and the components L1, L2, L3, and L4. This comprehensive approach to defining both the compounds and the methods of their synthesis suggests a focus on the potential pharmaceutical applications of these compounds, although specific therapeutic uses are not detailed in the claims. Overall, the patent presents a structured framework for the development and application of these chemical compounds in a pharmaceutical context.
To know more about GlobalData’s detailed insights on Arrowhead Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
